Plus therapeutics and spectronrx announce radiotherapeutic manufacturing partnership

Austin, texas and indianapolis, nov. 06, 2024 (globe newswire) -- plus therapeutics , inc. (nasdaq: pstv), a clinical-stage pharmaceutical company developing targeted radiotherapeutics for central nervous system (cns) cancers, and spectronrx , a leading radiopharmaceutical contract developer and manufacturer, announced the signing of a manufacturing services agreement (msa) for the production of rhenium (186re) obisbemeda, an innovative radiotherapy for cns cancers, including leptomeningeal metastases and recurrent glioblastoma. “in 2025, we intend to begin late-stage clinical trials and are actively preparing for commercial level product demand, therefore now is the time to expand our supply chain and partner with leading radiopharmaceutical manufacturers such as spectronrx that can deliver for us and our patients,” said marc h.
PSTV Ratings Summary
PSTV Quant Ranking